Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer-Reference-Cited by-同舟云学术

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Published:2019-09-18 Issue:510 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Molina-Arcas Miriam¹²^ORCID,Moore Christopher¹^ORCID,Rana Sareena¹²,van Maldegem Febe¹^ORCID,Mugarza Edurne¹,Romero-Clavijo Pablo¹,Herbert Eleanor³⁴^ORCID,Horswell Stuart⁵^ORCID,Li Lian-Sheng⁶^ORCID,Janes Matthew R.⁶^ORCID,Hancock David C.¹^ORCID,Downward Julian¹²^ORCID

Affiliation:

1. Oncogene Biology, Francis Crick Institute, London NW1 1AT, UK.

2. Lung Cancer Group, Institute of Cancer Research, London SW3 6JB, UK.

3. Experimental Histopathology, Francis Crick Institute, London NW1 1AT, UK.

4. Royal Veterinary College, Hatfield AL9 7TA, UK.

5. Computational Biology Laboratories, Francis Crick Institute, London NW1 1AT, UK.

6. Wellspring Biosciences, San Diego, CA 92121, USA.

Abstract

Combined targeting of KRAS-G12C, mTOR, and IGF1R enhances and extends the response to recently developed KRAS-G12C inhibitors in lung cancer models.

Funder

Wellcome

H2020 European Research Council